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ABSTRACT 27 
Background. Vancomycin-resistant enterococcal (VRE) bacteraemia has a high mortality and 28 
continues to defy control. Antibiotic risk factors for VRE bacteraemia have not been adequately 29 
defined. We aimed to determine the risk factors for VRE bacteraemia focusing on duration of 30 
antibiotic exposure.  31 
Methods. A retrospective matched nested case-control study was conducted amongst hospitalised 32 
patients at Cambridge University Hospitals NHS Foundation Trust from 1st January 2006 to 31st 33 
December 2012. Cases who developed a first episode of VRE bacteraemia were matched 1:1 to 34 
controls by length of stay, year, specialty and ward type. Independent risk factors for VRE 35 
bacteraemia were evaluated using conditional logistic regression. 36 
Results. 235 cases were compared to 220 controls. Duration of exposure to parenteral vancomycin, 37 
fluoroquinolones, and meropenem were independently associated with VRE bacteraemia. Compared 38 
to patients with no exposure to vancomycin, those who received courses of 1-3 days, 4-7 days, or 39 
greater than 7 days had a stepwise increase in risk of VRE bacteraemia (conditional odds ratio (cOR) 40 
1.2 (95% confidence interval [CI] 0.4-3.8), 3.8 (95% CI 1.2-11.7), and 6.6 (95% CI 1.9-22.8), 41 
respectively). Other risk factors were presence of central venous catheter (cOR 8.7 [95% CI 2.6-42 
29.5]); neutropenia (cOR 15.5 [95% CI 4.2-57.0]); hypoalbuminaemia (cOR 8.5 [95% CI 2.4-29.5]); 43 
malignancy (cOR 4.4 [95% CI 1.6-12.0]); gastrointestinal disease (cOR 12.4 [95% CI 4.2-36.8]); or 44 
hepatobiliary disease (cOR 7.9 [95% CI 2.1-29.9]).  45 
Conclusions. Longer exposure to vancomycin, fluoroquinolones, or meropenem was associated with 46 
VRE bacteraemia. Antimicrobial stewardship interventions targeting high-risk antibiotics are required 47 
to complement infection control procedures against VRE bacteraemia.   48 
 3 
INTRODUCTION  49 
Over the last 20 years, vancomycin-resistant enterococci (VRE) have emerged as a major cause of 50 
healthcare-associated bacteraemia, disproportionally affecting immunocompromised and critically ill 51 
patients. 1 Enterococcus faecium has become responsible for most VRE infections following the global 52 
dissemination of a hospital-adapted lineage. 2 VRE bacteraemias are associated with increased costs 53 
of care, length of stay and mortality compared to vancomycin-susceptible enterococcal (VSE) 54 
bacteraemias. 3, 4 In contrast to other healthcare-associated infections, rates of VRE bacteraemia 55 
have failed to decline in response to a host of generic infection control interventions in different 56 
healthcare settings, 5-7 and are even increasing in some countries. 8 Consequently, the identification 57 
of modifiable risk factors for VRE bacteraemia remains a priority. 58 
 59 
Gut carriage of VRE is a major risk factor for VRE bacteraemia. Bloodstream infection may be 60 
preceded by high levels of VRE carriage in the gut. 9 In recipients of allogeneic stem cell transplants, 61 
this is observed in conjunction with loss of microbiota diversity (particularly anaerobes), a state 62 
termed enterococcal dominance. 10 Exposure to a range of antibiotics increases susceptibility to VRE 63 
intestinal colonisation and progression to high-level carriage and bacteraemia, although the effect of 64 
individual antibiotics varies at each step of this sequence of events. 11 The rate of progression from 65 
carriage to invasive infection is also affected by the comorbidities of the patient population. 12 Length 66 
of stay, adherence to infection control procedures and proximity to VRE colonised patients or a 67 
contaminated environment are additional modifiable factors that affect the risk of VRE 68 
colonisation.13  69 
 70 
A number of studies have identified risk factors for VRE bacteraemia, including haematological 71 
malignancy, renal insufficiency, acute severity of illness, immunosuppression/neutropenia, 72 
gastrointestinal disease or procedures, and modifiable factors such as antibiotic exposure. 14-24 73 
 4 
Vancomycin is the antibiotic most commonly implicated, but not all studies agree on its role. Lastly, 74 
few studies have quantified the effect of cumulative exposure to individual antibiotics. 15, 22, 23 75 
 76 
The aim of this study was to identify modifiable risk factors for VRE bacteraemia, in particular 77 
antibiotic exposure, using a nested case-control study design in a centre with high rates of VRE 78 
endemicity.  79 
 80 
METHODS 81 
Study Setting, Design and Participants 82 
A retrospective matched nested case-control study was conducted amongst hospitalised patients at 83 
Cambridge University Hospitals NHS Foundation Trust (CUH) in the United Kingdom (UK) from 1st 84 
January 2006 to 31st December 2012. This tertiary referral teaching hospital has 1,170 beds, 340,000 85 
occupied-bed-days per year, and a range of specialties including hepatology and hepatobiliary 86 
surgery, solid organ transplantation (kidney, liver, pancreas and small bowel/multivisceral), adult 87 
haematopoietic stem cell transplantation, paediatric haemato-oncology, and general and 88 
neurocritical intensive care units (ICU). CUH has reported the highest number of VRE bacteraemias in 89 
England in the national mandatory surveillance scheme from 2003-2012 (426/6246, or 7% of national 90 
total out of 161 hospital Trusts). An active antimicrobial stewardship programme was in place 91 
throughout the duration of the study, including prescribing guidelines and regular antimicrobial 92 
rounds. Infection control practices targeting VRE did not change during the study period, however a 93 
line care bundle was implemented during 2006 and a deep clean programme in 2007. Vancomycin 94 
and teicoplanin susceptibility was determined by disk diffusion using British Society of Antimicrobial 95 
Chemotherapy breakpoints (http://www.bsac.org.uk/wp-content/uploads/2012/02/BSAC-96 
Susceptibility-testing-version-143.pdf). Cases and controls were identified using the diagnostic 97 
laboratory information system and the hospital electronic database, respectively. Cases were 98 
consecutive inpatients with their first episode of VRE bacteraemia during the study period. Patients 99 
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with presumed contaminated blood cultures (single positive sets not necessitating the use of 100 
targeted antibiotic therapy for symptom and bacteraemia resolution at the clinicians’ discretion) 101 
were excluded (Supplementary Table 1). Controls were matched to cases in a 1:1 ratio for the 102 
following: (i) duration of stay (matched to cases based on time from admission to day that positive 103 
blood culture was taken); (ii) year of admission; (iii) specialty; and (iv) ward type defined as general 104 
adult, adult ICU, or paediatric ward. Specialty and ward type were treated as time-varying variables 105 
and matched at the day of the bacteraemia. Matching for year of admission was chosen to minimise 106 
potential confounding that may arise due to changes in antimicrobial prescribing or infection control 107 
practices during the study period. Matching for specialty and ward type was used to account for 108 
underlying comorbidities that predispose to VRE infections and for changes in local unit VRE 109 
prevalence. Cases could serve as controls before becoming a case, and controls could serve as 110 
controls more than once. 25 111 
 112 
Covariates 113 
Demographic, epidemiological and clinical information were selected for inclusion based on a 114 
literature review of risk factors for VRE bacteraemia, and extracted from paper and electronic patient 115 
records. These included duration of hospital stay and prior ICU stay at CUH up to point of matching, 116 
in-patient transfer from another hospital at the start of the current admission, and cumulative length 117 
of stay in all wards and high-risk wards at CUH over the year prior to current admission. High-risk 118 
wards were those associated in the literature with increased risk of VRE colonisation and invasive 119 
disease (adult and paediatric haemato-oncology, solid organ transplant, nephrology, hepatology and 120 
ICU). 26 Mortality at 30 days was determined from hospital records or from an on-line national 121 
database (NHS Spine). Usage data for all antibacterial and antifungal agents (including treatment and 122 
prophylactic doses) was collected for 30 days prior to matching from paper local and referring 123 
hospital records and drug charts. Cut-offs for duration of antimicrobial exposure were chosen at 3 124 
days and 7 days in line with current antimicrobial stewardship recommendations where indication 125 
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for continuing antibiotics should be reviewed at 48-72 h and prolonged courses beyond one week are 126 
discouraged in the absence of a clear indication. 27 127 
 128 
Clinical parameters and comorbidities recorded at the time of matching included use of gastric acid 129 
suppressing medication; presence of central venous catheter (CVC); neutropenia (neutrophil count 130 
<500×106/L); immunosuppression (other than neutropenia); hypoalbuminaemia (albumin <30 g/dL); 131 
solid organ or haematological malignancy; solid organ or haematopoietic stem cell transplantation; 132 
liver cirrhosis; gastrointestinal disease; and hepatobiliary disease. VRE carriage was defined as 133 
growth of VRE from any clinical culture in the 12 months prior to matching. An additional list of 134 
candidate variables and definitions is provided in Supplementary material.  135 
 136 
Statistical methods 137 
Our primary analysis examined the association between exposure to antimicrobials and the 138 
subsequent development of VRE bacteraemia. We used univariable and multivariable logistic 139 
regression models conditioned on the matched variable to estimate conditional odds ratios (cORs) 140 
and 95% confidence intervals (CIs) for the association between independent factors and the 141 
development of VRE bacteraemia. Variables were evaluated in a multivariable model if differences 142 
between cases and controls on univariable analysis showed a P value less than 0.2. The final 143 
multivariable model was built using Hosmer and Lemeshow’s purposeful selection. 28 Statistical 144 
analyses were performed using the Stata 12.1 software package (Stata Corp., USA).  145 
 146 
Ethics statement 147 
The study was approved by the local Research Ethics Committee (reference 13/EE/0044) and by the 148 
CUH Research and Development Department (reference A092807).  149 
 150 
RESULTS 151 
 7 
We identified 295 patients with 331 episodes of VRE bacteraemia from 1st January 2006 to 31st 152 
December 2012 (average annual incidence of 12.8/100,000 occupied-bed-days) (Figure 1). These 153 
originated from a base of 218,223 patients that had 380,242 overnight admissions from 5th 154 
November 2005 to 31st December 2012. Twelve patients could not be assessed due to missing paper 155 
records and 38 were excluded as their positive blood cultures were deemed contaminants by the 156 
treating doctors.  Of the remaining 245 patients, 235 defined as cases were successfully matched to 157 
220 controls. Eight cases also served as controls before becoming a case, and seven controls were 158 
matched to cases more than once, resulting in 235 paired comparisons.  159 
 160 
The demographic, clinical and microbiological characteristics of 235 cases and 220 controls are 161 
shown in Table 1. Comparison between the two groups confirmed effective matching for age, 162 
gender, speciality, ward type, year, and length of stay. Thirty cases were younger than 16 years, and 163 
of the adult patients 55 (27%) were located in an ICU at the onset of infection. VRE bacteraemia 164 
occurred in cases a median of 16 days following admission to CUH. E. faecium accounted for 91% and 165 
the VanA phenotype (resistance to both vancomycin and teicoplanin) for 87% of bacteraemias. The 166 
crude (all-cause) mortality at 30 days was higher in cases compared to controls (34% versus 13%). 167 
Only 2 deaths occurred in the paediatric population, both of which were cases. 168 
 169 
A univariable analysis was performed to identify risk factors associated with VRE bacteraemia (Table 170 
2 and Supplementary Table 2). This demonstrated associations with the following: cumulative length 171 
of stay on high-risk wards at CUH during the year preceding the current admission; in-patient 172 
transfer from another hospital; gastric acid suppression therapy; presence of CVC; neutropenia; solid 173 
organ tumour; severe renal failure; gastrointestinal disease; hepatobiliary disease; diabetes with end-174 
organ damage; and hypoalbuminaemia.  175 
 176 
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The univariable analysis also examined the association between VRE bacteraemia and antibiotic use 177 
(Table 3 and Supplementary Table 2). Both groups had high rates of overall exposure to antibiotics in 178 
the preceding 30 days, but cases received antibiotics more often and for longer durations. The 179 
commonest antibiotics prescribed in both groups were intravenous (IV) vancomycin, meropenem, 180 
fluoroquinolones, piperacillin-tazobactam and metronidazole. We found an association with VRE 181 
bacteraemia for cumulative antibiotic duration over the prior 30 days, and for exposure to IV 182 
vancomycin, meropenem, cephalosporins, fluoroquinolones, aminoglycosides, penicillins, and 183 
antifungals. The duration of exposure to IV vancomycin, meropenem, fluoroquinolones, 184 
cephalosporins, and antifungals was also associated with VRE bacteraemia.  185 
 186 
Factors that were significant in the univariable analysis were then used in a multivariable analysis to 187 
define independent risk factors for VRE bacteraemia (Table 4). After adjustment for comorbidities, 188 
when compared to patients who did not receive any IV vancomycin, those exposed for 1-3 days, 4-7 189 
days, or more than 7 days had a stepwise increase in risk for developing VRE bacteraemia (cOR of 1.2 190 
(95% CI 0.4-3.8), 3.8 (95% CI 1.2-11.7), and 6.6 (95% CI 1.9-22.8), respectively). Similar stepwise 191 
increases in cORs were observed for fluoroquinolones and meropenem.  Additional risk factors 192 
independently associated with an increased risk for VRE bacteraemia were: presence of CVC (cOR 8.7 193 
[95% CI 2.6-29.5]); neutropenia (cOR 15.5 [95% CI 4.2-57.0]); hypoalbuminaemia (cOR 8.5 [95% CI 194 
2.4-29.5]); solid organ tumour (cOR 4.4 [95% CI 1.6-12.0]); gastrointestinal disease (cOR 12.4 [95% CI 195 
4.2-36.8]); and hepatobiliary disease (cOR 7.9 [95% CI 2.1-29.9]). 196 
 197 
DISCUSSION 198 
In this study, we found that receiving IV vancomycin, fluoroquinolones, or meropenem was each 199 
associated with VRE bacteraemia. We also observed that the risk increased considerably when the 200 
duration of antibiotic exposure was longer than 72 hours and 7 days for each of these three agents, 201 
and that the effect was independent of other risk factors. To our knowledge, our study is the largest 202 
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to investigate risk factors for VRE bacteraemia and the first to have been performed in the UK, in a 203 
setting with high levels of VRE endemicity similar to the situation in the United States. These results 204 
not only demonstrate an association for these high-risk antibiotics, but also provide a clinically 205 
important message, encouraging the discontinuation of these agents within 48-72 hours of initiation 206 
when appropriate to minimise the risk of VRE bacteraemia. 207 
 208 
The multivariable model identified previously reported markers of disease severity that predispose to 209 
VRE bacteraemia (hypoalbuminaemia, neutropenia, and gastrointestinal disease). 16, 18, 23 It also 210 
identified hepatobiliary disease as an independent risk factor, which has not previously been 211 
distinguished from gastrointestinal disease. These conditions are likely to predispose a colonised 212 
patient to invasive disease through gut or biliary translocation and suggest that patients who develop 213 
VRE bacteraemia represent a subgroup of patients with more significant comorbidities than matched 214 
controls on same wards and specialties, irrespective of length of stay or nursing in ICU. The 215 
association between a CVC and VRE bacteraemia has been reported previously, and could represent 216 
a marker of severity of illness or a potential portal for infection. 18  217 
 218 
The role of vancomycin in promoting VRE acquisition is controversial and reported associations, or 219 
lack thereof, could be explained by study design. A meta-analysis of early studies investigating the 220 
role of vancomycin in hospital-acquired VRE colonisation or infection attributed strong associations 221 
to confounding by length of stay, control group selection and publication bias. 29 This goes against 222 
human experimental evidence where administration of glycopeptides orally led to gastrointestinal 223 
selection of VRE. 30 Two studies of VRE bacteraemia using controls without enterococcal bacteraemia 224 
have implicated vancomycin exposure as an independent risk factor, 31, 32 but two further recent 225 
studies with adequate sample size failed to demonstrate this effect. 18, 23 Both of the latter studies 226 
were conducted in Australia where vancomycin resistance was predominantly mediated by the vanB 227 
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operon. 6 This contrasts with the CUH and UK epidemiology where vancomycin resistance in VRE 228 
bacteraemia is predominantly mediated by vanA. 33, 34 229 
 230 
Carbapenem use has only been implicated as an independent risk factor of VRE compared to VSE 231 
bacteraemia in one published study. 14 However, since VRE was predominantly caused by ampicillin-232 
resistant VRE faecium and VSE by ampicillin-susceptible VSE faecalis, the effect could have been 233 
previously overestimated. 14 This is particularly the case as imipenem, which was the carbapenem 234 
used in this study, has higher efficacy against ampicillin-susceptible enterococci compared to other 235 
carbapenems. Our study supports the independent association of carbapenem use (meropenem) 236 
with VRE bacteraemia. Carbapenems have anaerobic activity which could promote VRE 237 
colonisation.35 A number of investigators have reported that antibiotics with anaerobic activity 238 
predispose to VRE colonisation, 9 but definitions of this group of antibiotics have not been applied 239 
consistently in the literature. Interestingly, piperacillin-tazobactam, an antibiotic with similar 240 
spectrum of activity to meropenem including anaerobic, was not associated with VRE bacteraemia 241 
here. This is consistent with murine experiments where administration of piperacillin-tazobactam 242 
was protective against the establishment of high-level VRE colonisation, 36 and with some 243 
observational studies where antimicrobial stewardship interventions involving replacement of 244 
cephalosporin use with piperacillin-tazobactam resulted in reduction of VRE colonisation. 11 245 
However, this effect was not noted by other investigators. 37 It is possible that meropenem was 246 
preferentially used in sicker patients in our study or that the lack of observed association with 247 
piperacillin-tazobactam was due to insufficient power. The impact of switching therapy from 248 
meropenem to piperacillin-tazobactam on the acquisition of VRE infection merits further 249 
investigation.  250 
 251 
Fluoroquinolone use has often been identified as a risk factor for VRE bacteraemia on univariable 252 
analysis but not following adjustment for other factors. 14, 18, 21, 23 In a meta-analysis of ten studies 253 
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reported by Harbarth et al., 38 fluoroquinolone use was associated with VRE colonisation or infection 254 
(pooled OR 2.33, 95% CI 1.5-3.61). In a recent prospective observational study Sanchez-Diaz et al. 255 
showed that long-term prophylaxis with levofloxacin in neutropenic haemato-oncology patients led 256 
to intestinal overgrowth of hospital-adapted clones of E. faecium. 39   257 
 258 
Placing our findings into the context of the published literature, longer courses of fluoroquinolones 259 
and meropenem may promote gut colonisation with hospital-adapted strains of E. faecium (VSE or 260 
VRE depending on local epidemiology). Plausibly, in settings where VRE is endemic, IV vancomycin 261 
could shift the balance of the gut population and/or invasive isolates from VSE to VRE 40 thus 262 
increasing the risk of VRE bacteraemia in susceptible patients. Gastrointestinal or hepatobiliary 263 
insults or presence of a CVC could constitute portals of entry for the infection in heavily colonised 264 
patients, particularly those with neutropenia.  265 
 266 
This study has a number of limitations. It was conducted in a single centre with high endemicity of 267 
VRE and so the findings may not apply to other settings, particularly those that utilise active 268 
screening programmes for VRE. However, the infection control practices in our hospital are typical 269 
for the UK and the study included patients from all high-risk groups including adult and paediatric 270 
populations. Thirty-eight patients with positive blood cultures for VRE were excluded as 271 
contaminants based on contemporaneous clinical assessment. These patients had a comparable 30-272 
day mortality to the control population (8%) and repeat blood cultures performed in 33 patients 273 
(87%) were negative in the absence of treatment supporting their exclusion. Cases and controls 274 
differed in the duration of prior hospitalisations both at CUH and elsewhere, and despite adjusting 275 
for these in the model, there could be residual confounding. We did not adjust for the Charlson 276 
comorbidity index as this score is not applicable to children, but analysed its individual components 277 
instead. Also, we did not adjust for acute severity of illness using the Pitt bacteraemia or other 278 
scores, as we could not ascertain whether the observed score was a cause or an effect of the 279 
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bacteraemia. We opted against using a case-case-control design which has been advocated for 280 
studies of antibiotic resistance to enable distinction between risk factors predisposing to infection by 281 
a particular organism as opposed to those specific to its resistance marker. 41 This decision was made 282 
because VRE bacteraemia tends to occur later in the course of hospitalisation than VSE bacteraemia, 283 
18, 23 so accounting for markers of hospital exposure related to length of stay would not have been 284 
possible. Consequently, some of the findings should be interpreted as potentially predisposing to 285 
both VSE and VRE bacteraemia rather than just VRE as explained above. 286 
 287 
In conclusion, this study identified longer duration of exposure to vancomycin, fluoroquinolones or 288 
meropenem as independent risk factors for VRE bacteraemia. Antibiotic formulary interventions 289 
have not been proven to be effective in reducing VRE bacteraemia but are generally accepted as part 290 
of a response to curb resistant pathogens, in addition to infection control interventions such as hand 291 
washing and improved cleaning protocols. 42, 43 This study suggests that targeting the use of a single 292 
antibiotic in an endemic setting is unlikely to impact significantly on rates of VRE bacteraemia. 293 
Instead, a combination of approaches including antimicrobial stewardship focusing on limiting the 294 
duration of high-risk antibiotics in addition to infection control interventions would be required to 295 
curb the rates of VRE bacteraemia. 296 
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Figure 1. Selection of study population for nested case-control comparison of risk factors for 426 
vancomycin-resistant enterococcal (VRE) bacteraemia.  427 
428 
  429 
Data available for analysis 
  Cases  Controls 
Antibiotic exposure  n=233  n=234  
Antibiotic duration  n=232  n=231 
Neutropenia duration  n=233 
Gastrointestinal disease  n=233 
   
380,242 overnight admissions between 5 th November 2005 
and 31st December 2012 
(218,223 patients) 
12 patients not assessed for eligibility: Notes 
unavailable   
48 patients excluded    
1. 38 ineligible: Contaminated blood cultures    
2. 10 eligible but not included: Unable to match  
 
295 patients with VRE bacteraemia 
between 1st Jan. 2006 and 31st Dec. 2012 
283 patients assessed for eligibility 
 
235 cases 
 
220 controls matched 1:1 by admission 
year, specialty, ward type and length of 
stay 
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Table 1. Demographic, clinical and microbiological characteristics of cases and controls 430 
Characteristic Cases: Patients 
with VRE 
bacteraemia 
(n=235) 
Controls: 
Patients 
without VRE 
bacteraemia 
(n=220) 
P value 
Age (years), median (IQR) 56.6 (39.0-66.7) 57.8 (42.2-69.5) 0.34 
Male 145 (61.7) 127 (57.7) 0.47 
Year of admission    
  2005 2 (0.9) 2 (0.9) N/A 
  2006 34 (14.5) 33 (15.0)  
  2007 42 (17.9) 39 (17.7)  
  2008 30 (12.8) 29 (13.2)  
  2009 39 (16.6) 33 (15.0)  
  2010 31 (13.2) 29 (13.2)  
  2011 25 (10.6) 25 (11.4)  
  2012 32 (13.6) 30 (13.6)  
Ward at time of bacteraemia    
  Adult general 150 (63.8) 141 (64.1) N/A 
  Adult ICU 55 (23.4) 53 (24.1)  
  Paediatric 30 (12.8) 26 (11.8)  
Time from admission to bacteraemia 
(cases) and matching (controls) (days), 
median (IQR)a 
16 (9-31) 16 (8-31) N/A 
Lead specialty type at time of matchingb    
  Adult haematology 67 (28.5) 57 (25.9) N/A 
  Adult oncology 4 (1.7) 4 (1.7)  
  Adult medicine 66 (28.1) 65 (29.6)  
  Adult solid organ transplant 31 (13.2) 31 (14.1)  
  Adult surgery 37 (15.7) 37 (16.8)  
  Paediatric haemato-oncology 30 (12.8) 26 (11.8)  
Enterococcus faecalis 17 (7.2)   
Enterococcus faecium 214 (91.1)   
Other enterococcal speciesc 4 (1.7)   
VanA 202/232 (87.1)   
Death within 30 days of matching 79 (33.6) 28 (12.7) <0.001d 
 431 
Data are presented as number (%) unless indicated otherwise. 432 
Abbreviations: ICU, intensive care unit; IQR, interquartile rate; VRE, vancomycin-resistant 433 
enterococcus.  434 
N/A, not applicable: these variables were used to match cases and controls.  435 
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a The onset of bacteraemia for 27 of 235 cases was within 2 days post hospital admission; for 25 of 27 436 
of these cases, there was healthcare contact in the preceding 3 months.   437 
b Lead specialties included 18 different options used for matching, grouped under six categories in 438 
this table. For full list of specialties see Supplementary material. 439 
c Other species were Enterococcus raffinosus (1), mixed E. faecalis and E. faecium (1), mixed E. 440 
faecium and E. raffinosus (1), and one unspeciated. Both E. raffinosus isolates were phenotypically 441 
VanA.  442 
d Fisher’s exact test443 
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Table 2: Risk factors for vancomycin-resistant enterococcal bacteraemia  
 
Variable Cases (n=235) Controls 
(n=235) 
Crude cOR (95% CI) P value 
Comorbidities     
   Solid organ tumour 60 (25.5) 42 (17.9) 1.7 (1.0-2.8) 0.03 
Haematological malignancy 94 (40.0) 86 (36.6) 1.6 (0.8-3.2) 0.17 
Neutropenia  89 (37.9) 38 (16.2) 6.7 (3.3-13.4) <0.001 
Severe renal failure on admission 15 (6.4) 6 (2.6) 3.3 (1.1-10.0) 0.04 
Liver cirrhosis 29 (12.3) 24 (10.2) 2.0 (0.7-5.9) 0.21 
Gastrointestinal disease 67/233 (28.8) 25 (10.6) 4.6 (2.5-8.6) <0.001 
Hepatobiliary disease 41 (17.5) 22 (9.4) 3.4 (1.5-7.4) 0.003 
Diabetes (with end-organ damage) 16 (6.8) 5 (2.1) 4.7 (1.3-16.2) 0.02 
Hypoalbuminaemia 209 (88.9) 150 (63.8) 8.4 (4.0-17.4) <0.001 
Clinical exposures     
Gastric acid suppression  203 (86.4) 183 (77.9) 1.9 (1.1-3.2) 0.01 
Central venous catheter  197 (83.8) 153 (65.1) 5.4 (2.8- 10.6) <0.001 
Immunosuppression (other than 
neutropenia) 
146 (62.1) 143 (60.9) 1.2 (0.6-2.1) 0.65 
Abdominal procedures  85 (36.2) 71 (30.2) 1.6 (1.0-2.8) 0.07 
Prior microbiology     
VRE grown from clinical sample within 1 
year prior to matching 
38 (16.2) 25 (10.6) 1.6 (0.9-2.6) 0.09 
Hospital exposure     
   Cumulative length of stay at CUH within 
1 year of current admission (all wards) 
    
      0 days 88 (37.4) 101 (43.0) 1.0 0.16 
      1-14 days 43 (18.3) 49 (20.9) 1.1 (0.6-1.8)  
      >14 days 104 (44.3) 85 (36.2) 1.5 (1.0-2.4)  
   Cumulative length of stay at CUH within 
1 year of current admission (high-risk 
wards)a 
    
      0 days 121 (51.5) 142 (60.4) 1.0 0.05 
      1-14 days 33 (14.0) 30 (12.8) 1.5 (0.8-2.7)  
      >14 days 81 (34.5) 63 (26.8) 1.8 (1.1-3.0)  
ICU stay current admission 87 (37.0) 77 (32.8) 1.6 (0.9-2.9) 0.14 
Transfer from another hospital 65 (27.7) 44 (18.7) 1.7 (1.1-2.6) 0.02 
 
Data are presented as number (%) of patients unless indicated otherwise.  
Abbreviations: CI, confidence intervals; cOR, conditional odds ratio; CUH, Cambridge University Hospitals; 
ICU, intensive care unit; IQR, interquartile rate; IV, intravenous; PO, per os (oral administration); VRE, 
vancomycin-resistant enterococcus. 
a High-risk wards included: adult and paediatric haemato-oncology, solid organ transplant, nephrology, 
hepatology and ICU.  
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Table 3: Association between antimicrobial exposure and vancomycin-resistant enterococcal 
bacteraemia  
 
Antimicrobial Cases (n=235) Controls 
(n=235) 
Crude cOR (95% 
CI) 
P value 
   Vancomycin (IV) 169/233 (72.5) 123/234 (52.6) 3.3 (2.0-5.4) <0.001 
   Vancomycin (PO) 10/233 (4.3) 8/234 (3.4) 1.3 (0.5-3.2) 0.64 
   Cephalosporins 33/233 (14.2) 18/234 (7.7) 2.2 (1.1-4.2) 0.02 
   Fluoroquinolones 144/234 (61.5) 100/234 (42.7) 2.5 (1.6-3.8) <0.001 
   Amoxicillin-clavulanic acid  36/233 (15.5) 31/234 (13.3) 1.2 (0.7-2.1) 0.49 
   Piperacillin-tazobactam  74/233 (31.8) 63/234 (26.9) 1.4 (0.8-2.3) 0.21 
   Meropenem  157/233 (67.4) 109 (46.4) 2.8 (1.8- 4.3) <0.001 
   Metronidazole  70/234 (29.9) 54/234 (23.1) 1.5 (1.00-2.4) 0.07 
   Aminoglycosides 53/233 (22.8) 35/234 (15.0) 2.00 (1.1-3.3) 0.02 
   Penicillins  50/233 (21.5) 36/234 (15.4) 1.8 (1.0-3.0) 0.05 
   Macrolides 31/233 (13.3) 42 (17.9) 0.7 (0.4-1.2) 0.16 
   Antifungals  167/233 (71.7) 128 (54.5) 3.0 (1.8-5.1) <0.001 
Antimicrobial Duration 
   Vancomycin IV duration None 64/233 (27.5) 111/234 (47.4) 1.0 <0.001 
 1 to 3 days 28/233 (12.0) 40/234 (17.1) 1.5 (0.8-2.9)  
 4 to 7 days 49/233 (21.0) 37/234 (15.8) 3.2 (1.6-6.0)  
 >7 days 92/233 (39.5) 46/234 (19.7) 5.4 (2.9-10.0)  
   Fluoroquinolone duration None 90/232 (38.8) 134/233 (57.5) 1.0 <0.001 
 1 to 3 days 32/232 (13.8) 27/233 (11.6) 2.0 (1.1-3.7)  
 4 to 7 days 39/232 (16.8)( 25/233 (10.7) 2.6 (1.4-4.8)  
 >7 days 71/232 (30.6) 47/233 (20.2) 2.7 (1.6-4.7)  
   Meropenem duration None 76/233 (32.6) 126/231 (54.6) 1.0 <0.001 
 1 to 3 days 27/233 (11.6) 18/231 (7.8) 2.6 (1.3-5.4)  
 4 to 7 days 39/233 (16.7) 35/231 (15.2) 2.1 (1.2-3.8)  
 >7 days 91/233 (39.1) 52/231 (22.5) 4.3 (2.4-7.7)  
 
Data are presented as number (%) of patients unless indicated otherwise. 
Abbreviations: CI, confidence intervals; cOR, conditional odds ratio; CUH, Cambridge University Hospitals; 
ICU, intensive care unit; IQR, interquartile rate; IV, intravenous; PO, per os (oral administration); VRE, 
vancomycin-resistant enterococcus. 
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Table 4: Independent risk factors associated with vancomycin-resistant enterococcal bacteraemia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Only risk factors found to be statistically significant on multivariable analysis are shown.  
Abbreviations: CI, confidence interval; cOR, conditional odds ratio; IV, intravenous. 
 
 
Variables Adjusted cOR  (95% CI) P value 
Vancomycin IV duration (days) None 1.0 0.004 
 1 to 3 1.2 (0.4-3.8)  
 4 to 7 3.8 (1.2-11.7)  
 >7 6.6 (1.9-22.8)  
Fluoroquinolone duration (days) None 1.0 <0.001 
 1 to 3 1.3 (0.4-3.7)  
 4 to 7 4.5 (1.6-12.9)  
 >7 6.9 (2.4-20.0)  
Meropenem duration (days) None 1.0 0.03 
 1 to 3 1.8 (0.5-6.4)  
 4 to 7 2.3 (0.8-6.3)  
 >7 3.5 (1.3-10.0)  
Central venous catheter 8.7 (2.6-29.5) 0.001 
Neutropenia  15.5 (4.2-57.0) <0.001 
Hypoalbuminaemia 8.5 (2.4-29.5) 0.001 
Solid organ tumour 4.4 (1.6-12.0) 0.003 
Hepatobiliary disease 7.9 (2.1-29.9) 0.002 
Gastrointestinal disease 12.4 (4.2-36.8) <0.001 
